MAP9

Across TCGA pan-cancer cohorts, MAP9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP9 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP9 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where MAP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.469	0.902	.010	22	view →
CCRCC	DFS	Tertile	III,IV	0.198	1.000	.024	6	view →
PDAC	OS	Median	III,IV	0.716	0.390	.024	5	view →
UCEC	DFS	Median	III,IV	0.880	0.499	.036	4	view →
GBM	DFS	Quartile	All	0.858	0.626	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP9–LSCC (DFS)

Open the LSCC breakdown →